Chinese Biotech
Asset-level deep dives on China-originated drugs, built from filings and trial registries.
Afuresertib: an AKT inhibitor that "won its endpoint but lost on position"
Laekna's oral pan-AKT inhibitor hit its Phase 3 endpoint, but it is filing into a race where rival capivasertib is already approved and NRDL-reimbursed — so the asset's future is a game of BD monetization, not self-commercialization.
Sep 26, 2026 · 18 min read→Chinese Biotech / BL-M14D1BL-M14D1 + atezolizumab: how does a DLL3 ADC that is "cash-rich but treading on others' heels" take on 1L small cell lung cancer?
Biokin's DLL3 ADC posted a 62% response rate at ASCO 2026, but it is late against Zai Lab and tarlatamab — the real story is how a BMS-funded platform company hedges a latecomer position with a bold chemo-free 1L bet plus "combination + going global + timely licensing."
Sep 26, 2026 · 22 min read→Chinese Biotech / ecnoglutide (XW003)Ecnoglutide (XW003)
The world's first cAMP-biased GLP-1 — a panoramic analysis of Sciwind's China-first clinical development, from SLIMMER's 2.0% AE dropout to the US$495M Pfizer China deal and a US$2.4B global licensing map.
Sep 26, 2026 · 8 min read→Chinese Biotech / eftansomatropin alfa (TJ101)Withdraw, refile, fall behind: the localization trade-off behind eftansomatropin alfa
Tianjing voluntarily withdrew an already-queued import filing to redo manufacturing costs — trading ~20 months of launch timing for a cost structure that might survive the NRDL price collapse in long-acting growth hormone.
Sep 26, 2026 · 22 min read→Chinese Biotech / ivonescimab (AK112)How did a Chinese bispecific top the global forecast rankings?
Evaluate ranked ivonescimab — Akeso/Summit's PD-1×VEGF bispecific — the most valuable pipeline asset at US$25B+ risk-adjusted NPV on two China head-to-head wins, but the US$25B case still hinges on FDA's November 2026 decision and global readouts.
Sep 26, 2026 · 20 min read→Chinese Biotech / LaikangqitamabLaikangqitamab (LZM012): a strong hand as "China's first dual-target", played into China's most cutthroat autoimmune race
It beat secukinumab head-to-head, yet never faced the real global benchmark — bimekizumab landed in China first — and Livzon, not the molecule's academic originator, holds the steering wheel.
Sep 26, 2026 · 20 min read→Chinese Biotech / LerodalcibepLerodalcibep: a molecule with "no suspense at all" — why does entering China turn it into a hard problem?
US-approved with its China BLA accepted, lerodalcibep is clinically certain — but it enters a Chinese PCSK9 market where seven rivals already fought the price war, so commercialization is the only question that matters.
Sep 26, 2026 · 16 min read→Chinese Biotech / RXIM002On the same road, a Chinese company has already published its data in NEJM
RiboX's circular RNA in vivo CAR-T cleared FDA IND in August 2026 — but "world's first" needs its qualifiers, and the asset now hinges on three non-technical gaps: public clinical numbers, a freedom-to-operate opinion, and funding visibility.
Sep 26, 2026 · 22 min read→Chinese Biotech / RentosertibRentosertib: A Panoramic Analysis of Its China Development Strategy
The world's first end-to-end AI-discovered TNIK inhibitor to reach patients — China Phase IIa GENESIS-IPF showed an FVC-improvement signal, CDE granted breakthrough designation, an inhaled formulation got its IND; the next leg is a pivotal where liver safety and SOC combination are the hardest questions.
Sep 26, 2026 · 25 min read→Chinese Biotech / RoconkibartRoconkibart: "the fifth domestic entry ticket" How Junshi Biosciences can make its second pillar stand
A follower IL-17A molecule with leader-level data — 90.9% PASI 90 at week 16 — staked as Junshi's "second pillar" after toripalimab's pioneer-to-follower lesson; whether it stands depends on the next 12 months of execution, not trials.
Sep 26, 2026 · 17 min read→Chinese Biotech / supaglutide alfa (Yinuoqing)Supaglutide alfa: holding an "ultra-long-acting" trump card, can Yinnuo Pharma play differentiation in the GLP-1 red ocean?
First domestic "ultra-long-acting human-sequence" GLP-1 to enter the NRDL; early weight-loss data in double digits, every-two-weeks dosing validated — suspense lies in the pivotal Phase 3 still to come.
Sep 26, 2026 · 18 min read→Chinese Biotech / asandeutertinib (TY-9591)Asandeutertinib approved: it won the head-to-head, but arrived two years late to its position
On Aug 27, 2026 TYK's deuterated third-gen EGFR-TKI got conditional NMPA approval — the only molecule to statistically beat osimertinib head-to-head on an intracranial primary endpoint, but the brain-metastasis label was taken two years earlier.
Sep 26, 2026 · 25 min read→Chinese Biotech / VCT220 (CX11)The first domestic oral small-molecule GLP-1 to read out a local Chinese Phase 3: how far has VCT220 sold itself?
May 18, 2026 Phase 3 topline — 840 Chinese patients, 52 weeks, −12.2%/−12.4% weight loss vs 1.3% placebo, 1.8% discontinuation, no liver toxicity signal, NDA imminent.
Sep 26, 2026 · 17 min read→Chinese Biotech / YL201YL201: the world's only Phase 3 in nasopharyngeal carcinoma
Jan 8, 2026 — Roche took exclusive ex-China rights for a US$570M upfront (near-term milestones incl.), China rights retained by MediLink; largest Chinese ADC upfront so far in 2026.
Sep 26, 2026 · 19 min read→